FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to allergology and immunology, and can be used to determine the stage of atopic dermatitis. The inflammatory marker IL-36 is isolated in the patient’s blood serum by enzyme immunoassay. For this purpose, 100 mcl of sample dilution solution and 100 mcl of blood serum of a patient with atopic dermatitis are injected into the wells of the tablet. Incubating for 120 minutes while shaking on a shaker at a temperature of 37±1°С and 700 rpm and washing the tablet 5 times with a washing solution. After that, 100 mcl of the IL-36 inflammatory marker is introduced into the wells and incubated for 60 minutes when shaken on a shaker at a temperature of 37±1°С and 700 rpm. Then the tablet is washed 5 times with a washing solution and streptavidin-horseradish peroxidase is added to all wells and incubated for 30 minutes while shaking on a shaker at a temperature of 37±1°С and 700 rpm and wash the tablet 5 times with a washing solution. 100 ml of tetramethylbenzidine plus is introduced into the wells and incubated in a place protected from light for 25 minutes at a temperature from 18°C to 25°C. After adding the stop reagent to the wells of the tablet, the optical density of the solutions is measured on a vertical scanning spectrophotometer in the two-wave mode of 450 nm and 620 nm. With the values of the IL-36 inflammatory marker in the blood serum from 0.02 to 600 pg/ml, the stage of remission of atopic dermatitis is determined. With the values of the IL-36 inflammation marker in the blood serum from 601 pg/ml to 9800 pg/ml, the stage of exacerbation of atopic dermatitis is determined.
EFFECT: method provides an opportunity to increase the accuracy of determining the stage of atopic dermatitis, to give an objective assessment of it and to improve the diagnosis of this disease by determining the concentration of IL-36 in the patient’s blood serum, which is a specific marker of inflammation.
1 cl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR IMMUNOLOGICAL PREDICTION OF ACUTE CEREBRAL CIRCULATION DISORDERS | 2023 |
|
RU2820071C1 |
METHOD OF IMMUNOLOGICAL PREDICTION OF SUDDEN CORONARY DEATH | 2023 |
|
RU2810015C1 |
METHOD FOR PREDICTION OF SEVERITY OF ATOPIC DERMATITIS IN CHILDREN | 2019 |
|
RU2711746C1 |
GASTRIC CANCER IMMUNODIAGNOSIS METHOD | 2023 |
|
RU2818734C1 |
METHOD FOR IMMUNODIAGNOSIS OF STOMACH CANCER | 2014 |
|
RU2580309C1 |
PROGNOSIS METHOD OF UVEITIS DEVELOPMENT IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS | 2016 |
|
RU2613056C1 |
METHOD FOR PREDICTION OF SEVERITY OF ATOPIC DERMATITIS IN CHILDREN | 2017 |
|
RU2677481C1 |
METHOD OF TREATMENT OF ATOPIC DERMATITIS | 2007 |
|
RU2340348C1 |
METHOD FOR DETERMINING THE ACTIVITY OF NEUTRALISING ANTIBODIES AGAINST SARS-CoV-2 IN THE SERUM OR PLASMA OF PEOPLE WITH PAST CASES OF COVID-19 OR VACCINATED WITH PREVENTIVE VACCINES AGAINST THE NOVEL CORONAVIRUS INFECTION COVID-19 USING A SET OF ENZYME IMMUNOASSAY REAGENTS CONTAINING A RECOMBINANT RECEPTOR-BINDING DOMAIN (RBD) OF SURFACE GLYCOPROTEIN S OF CORONAVIRUS SARS-CoV-2 AND RECOMBINANT HUMAN RECEPTOR ACE2 | 2021 |
|
RU2784655C1 |
METHOD FOR ASSESSING THE PROBABILITY OF DEVELOPING UNFAVORABLE HEART LEFT VENTRICULAR REMODELING IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION WITH ST SEGMENT ELEVATION | 2021 |
|
RU2770285C1 |
Authors
Dates
2022-05-19—Published
2021-09-22—Filed